|
|||||
|
|
Recent advances in developing polymeric micelles for treating cancer: Breakthroughs and bottlenecks in their clinical translation |
|
| Institution: | 1. School of Pharmaceutical Sciences, Lovely Professional University, Jalandhar-Delhi G.T Road, Phagwara 144411, Punjab, India;2. Department of Biotechnology, School of Engineering & Technology (SET), Sharda University, Greater Noida, 201310 Uttar Pradesh, India;3. Tatyasaheb Kore College of Pharmacy, Warananagar, Panhala, Kolhapur, Maharashtra 416113, India;4. Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Matunga, Mumbai, Maharashtra 400019, India;5. Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, NSW 2007, Australia;6. Faculty of Health, Australian Research Centre in Complementary and Integrative Medicine, University of Technology Sydney, Ultimo, NSW 2007, Australia |
| Abstract: | Polymeric micelles (PMs) have been explored pre-clinically for the delivery of chemotherapeutics to treat cancer. Their unique features, such as easy surface functionalization, stimuli-responsiveness, good stability, ability to modify drug release, enhanced permeation and retention effect, and potential to encapsulate more than one type of therapeutic molecules at a time, make them unique carriers for the targeted delivery or for enhancing the bioavailability of chemotherapeutics. PMs can also be used as theranostic nanocarriers for the mapping of drug therapy along with tumor imaging in patients with cancer. This review focuses on the limitations of existing treatment strategies and on innovative approaches employed for the functionalization of PMs for targeting cancer cells. In addition, the bottlenecks associated with the translation of PMs from the laboratory to clinics are also discussed. |
| Keywords: | Cancer Polymeric micelles Site-specificity Theranostic Clinical applications ABC"} {"#name":"keyword" "$":{"id":"k0035"} "$$":[{"#name":"text" "_":"Amphiphilic block copolymer BCS"} {"#name":"keyword" "$":{"id":"k0045"} "$$":[{"#name":"text" "_":"Biopharmaceutical classification system CMC"} {"#name":"keyword" "$":{"id":"k0055"} "$$":[{"#name":"text" "_":"Critical micelle concentration DOX"} {"#name":"keyword" "$":{"id":"k0065"} "$$":[{"#name":"text" "_":"Doxorubicin EPR"} {"#name":"keyword" "$":{"id":"k0075"} "$$":[{"#name":"text" "_":"Enhanced permeability and retention effect FDA"} {"#name":"keyword" "$":{"id":"k0085"} "$$":[{"#name":"text" "_":"US Food and Drug Administration GFP"} {"#name":"keyword" "$":{"id":"k0095"} "$$":[{"#name":"text" "_":"Green fluorescent protein GSH"} {"#name":"keyword" "$":{"id":"k0105"} "$$":[{"#name":"text" "_":"Reduced glutathione LCST"} {"#name":"keyword" "$":{"id":"k0115"} "$$":[{"#name":"text" "_":"Lower critical solution temperature mPEG"} {"#name":"keyword" "$":{"id":"k0125"} "$$":[{"#name":"text" "_":"MethoxyPEG NIR"} {"#name":"keyword" "$":{"id":"k0135"} "$$":[{"#name":"text" "_":"Near infra-red PCL"} {"#name":"keyword" "$":{"id":"k0145"} "$$":[{"#name":"text" "_":"Polycaprolactone PEG"} {"#name":"keyword" "$":{"id":"k0155"} "$$":[{"#name":"text" "_":"Polyethylene glycol PEO"} {"#name":"keyword" "$":{"id":"k0165"} "$$":[{"#name":"text" "_":"Polyethylene oxide PLA"} {"#name":"keyword" "$":{"id":"k0185"} "$$":[{"#name":"text" "_":"Polylactic acid PM"} {"#name":"keyword" "$":{"id":"k0195"} "$$":[{"#name":"text" "_":"Polymeric micelle PNIPAM"} {"#name":"keyword" "$":{"id":"k0205"} "$$":[{"#name":"text" "_":"Poly(N-isopropylacrylamide) PTX"} {"#name":"keyword" "$":{"id":"k0215"} "$$":[{"#name":"text" "_":"Paclitaxel ROS"} {"#name":"keyword" "$":{"id":"k0225"} "$$":[{"#name":"text" "_":"Reactive oxygen species siRNA"} {"#name":"keyword" "$":{"id":"k0235"} "$$":[{"#name":"text" "_":"Small interfering RNA |
| 本文献已被 ScienceDirect 等数据库收录！ | |